Condensed Consolidated Statements of Cash Flows - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities
Net loss	$ (173,633)	$ (98,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	18,125	15,267
Depreciation and amortization	795	899
Non-cash interest expense	7,987	6,194
Non-cash accretion & amortization of short-term investments	(3,562)	(4,299)
Non-cash accretion of non-current liability	1,927
Non-cash rent expense	181	192
Change in fair value of embedded derivative liability	(790)	(20)
Gain on settlement of forward contract	(8,900)
Acquired IPR&D assets classified as investing activities	92,385	5,650
Changes in operating assets and liabilities:
Accounts receivable	(2,731)	(7,607)
Inventory	(3,370)	(3,260)
Prepaid expenses and other current assets	287	1,540
Deferred revenue		(148)
Other long-term assets, net	2,249	1,123
Accounts payable, accrued expenses and other liabilities	(769)	5,828
Net cash used in operating activities	(69,819)	(77,523)
Investing activities
Purchases of short-term investments	(66,312)	(145,078)
Maturities of short-term investments	127,800	217,175
Acquisition of IPR&D assets	(40,000)	(5,395)
Purchases of property and equipment		(47)
Net cash provided by investing activities	21,488	66,655
Financing activities
Repayment of deferred royalty obligation	(5,756)	(2,657)
Proceeds from the exercise of stock options	7,755	894
Proceeds from issuance of common stock from ESPP	673	665
Gain on settlement of forward contract	8,900
Proceeds from Series A Preferred Stock, net of issuance costs	138,850
Net cash provided by (used in) financing activities	150,422	(1,098)
Effect of exchange rates on cash	(372)	(27)
Net increase (decrease) in cash, cash equivalents and restricted cash	101,719	(11,993)
Cash, cash equivalents and restricted cash at beginning of period	60,409	128,005
Cash, cash equivalents and restricted cash at end of period	162,128	116,012
Supplemental disclosure of non-cash investing and financing activities:
Non-current liability issued in exchange for the acquisition of IPR&D	$ 33,669
Issuance of common stock in exchange for IPR&D	18,716
Accretion of preferred stock dividends	$ 1,302
Holdback payable associated with acquisition of IPR&D assets, in accrued expenses		500
Transaction costs associated with acquisition of IPR&D assets, in accounts payable		$ 255